… treatment of SCCHN and colorectal carcinoma. Based on the results obtained in head and
neck cancer (Citation4), cetuximab has been recently proposed in the treatment … of cetuximab …

… role of cetuximab in the treatment of HNSCC. … cetuximab earlier in the course of treatment
of HNSCC, especially with concurrent chemo-RT and in the induction setting, would cetuximab …

… cells, including lymph node metastases. This drug, approved for treatment of squamous cell
carcinoma of … of SCCS who have been treated with palliative cetuximab. The drug was well …

… For these reasons, we conducted a randomized, phase 3 study to determine the effect of
adding cetuximab to radiotherapy in the treatment of patients with locoregionally advanced …

… cell carcinoma of the head and neck, as is cetuximab monotherapy. When cetuximab is …
to cisplatin monotherapy in the first-line treatment of recurrent or metastatic squamous cell …

… cell carcinomas, which commonly overexpress the EGF receptor (EGFR). Cetuximab is a …
, and in addition induces antibody-dependent cellular cytoxicity. In a randomized Phase III …

… cetuximab. In a large (n = 572) randomised trial in heavily pretreated patients with mCRC,
the addition of cetuximab treatment … plus cetuximab for squamous-cell carcinoma of the head …

… monoclonal antibody cetuximab in a panel of cultured squamous cell carcinoma cell lines. …
), is emerging as a promising agent for treatment of several cancers. As this antibody comes …

… to treat in the case of early disease progression. We also studied efficacy as a function of
skin toxicity as documented in SCCHN after cetuximab treatment. Since cetuximab sensitivity is …

… Twenty-four patients (68.6%) had a squamous cell carcinoma. Grade 3 adverse events
possibly related to cetuximab included dermatologic (n = 5), GI (n = 4), anemia (n = 2), …